BerGenBio - Invitation to conference call: interim update on Ph II clinical programme with selective AXL inhibitor bemcentinib being presented at ASCO
Bergen, Norway, 29 May 2018 – BerGenBio ASA (OSE:BGBIO) will host a conference call on Monday, 4 June at 8:30 AM CEST to present updated interim clinical and biomarker results from its ongoing Phase II development programme with selective AXL inhibitor bemcentinib. The data will be presented at the Annual American Society of Clinical Oncology (ASCO) meeting and at a reception hosted by BerGenBio (details below).Conference call details: The call will be hosted by BerGenBio senior management and take place on: Monday, 4 June 2018 at 8:30 AM CEST. To take part, please dial in 5-10